Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | PRNP | P04156 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.63 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.63 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16562254 | 0.80 | MEN1 (0.76) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16562130 | 0.80 | KMT2A (0.75) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL16562250 | 0.78 | PTPN1 (0.79) | MEN1KMT2AMAPTLMNAALDH1A1 | |
| SCHEMBL16553986 | 0.78 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4920831 | 0.77 | SCD (0.72) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL27182515 | 0.76 | MEN1 (0.65) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL2301706 | 0.72 | PIK3CD (0.67) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL8280120 | 0.71 | NPC1 (0.70) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL1307056 | 0.70 | MAPT (0.82) | MEN1KMT2ASMN1; SMN2MAPTLMNA | |
| SCHEMBL4912902 | 0.69 | TP53 (0.64) | MEN1KMT2ASMN1; SMN2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3041470-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | Board Of Regents Of the University Of Texas System (US) | 2016-07-13 | — | — | EP | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2015035051-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | MEN1 4719/4885KMT2A 1976/4885SMN1; SMN2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.